Media Release: Lifespot Health Completes Seng Vital Cannabis Vaporiser Acquisition & Opens Up Global Opportunities with Incorporation of Edibles & Soluble Tracking
- First-to-market with integrated Seng-Vitalä Cannamed® Bluetooth cannabis vaporising system
- Tracking and blue-tooth configuration, directly to users’ smart devices and doctor portal
- Significant advantages of Inhaler administration of cannabis over other formats
- The technology can also input data from edibles and drinks, opening up global opportunities
- Lifespot continues demonstrations of vaporising system to major cannabis players in Canada, USA, Israel, Australia and New Zealand
Lifespot Health Ltd (ASX: LSH) (“Lifespot” or “Company”) is pleased to announce that following the Company’s announcement on 18 September, Lifespot has now completed the acquisition of the remaining 50% of Seng Vital in order to now fully own the Seng Vital Company and smart cannabis vaporiser assets. This includes the Seng-Vital™ Cannamed® Bluetooth cannabis vaporising system, which provides a straightforward, secure and self-controlled method to deliver medicines.
According to a new market intelligence report by BIS Research the international recreational and medicinal vapor market was estimated at $11.43 billion in 2016 and is expected to grow over $86.43 billion by 2025, growing at a CAGR of 23.25% from 2017 to 2025. The unique properties of the smart cannabis vaporiser allows Lifespot to extend the device’s use into this international opportunity.
For the medical application, the use of an inhaler administration provides users with an easy, safe and self-controlled method to deliver medicines. For patient populations whom swallowing a tablet is not possible or medicines that are extensively metabolised prior to entry into the blood stream, the use of inhalation with the smart vaporiser provides many clinical advantages.
The Seng-Vital™ Cannamed® Bluetooth cannabis vaporising system, integrated with the Company’s Bodytel technology system, is not only restricted to vaporising, but can also input data from edibles and drinks, which opens Lifespot up to significant global opportunities in cannabis.
Rod Hannington, Chairman of Lifespot, said:
“Studies tell us that oral forms of cannabis-based therapeutics have been shown to have low bioavailability following oral administration, so the dose required may be considerably higher than required for inhalation. Accordingly, the potential use of a lower dose as an inhaled format may in turn have a safety benefit.”
“We believe that our integrated system is going to play an important role for medical cannabis and are looking forward to providing this excellent integrated platform to the cannabis sector.”
The new Seng-Vital™ Cannamed® “smart” Bluetooth vaporiser and accessories integrated system
The new Seng-Vital™ Cannamed® “smart” Bluetooth vaporiser App
The Company continues to conduct demonstrations to interested cannabis companies in Canada, USA, Israel, Australia and New Zealand.
For further information please contact:
Mr Justyn Stedwell, Company Secretary
Lifespot Health Ltd
T: +613 9191 01355
Rod North, Managing Director
Bourse Communications Pty Ltd
T: +613 9510 8309, M: +61 408 670 706
E: [email protected]
About Lifespot Health Ltd.
Lifespot Health, an ISO 13485 certified company, operates within the digital health sector and is focused on developing and commercialising medical diagnostic and monitoring technology. Lifespot Health systems and applications aim to bring efficiencies in the medical system to clients and end users, saving time and money.
Lifespot Health integrates software to combine enhanced sensor technology with self-learning algorithms, allowing patients and healthcare professionals to efficiently monitor chronic diseases and critical conditions on their personal and professional digital devices including Smartphone, iPad/Tablets and desktop.
For more information please visit: http://lifespot-health.com/